Tarng Der-Cherng
Department and Institute of Physiology, National Yang-Ming University, Taipei, Taiwan, ROC.
J Chin Med Assoc. 2007 Oct;70(10):424-9. doi: 10.1016/S1726-4901(08)70031-5.
Anemia is a frequently encountered problem of chronic kidney disease (CKD) and deteriorates as renal function declines. Anemia increases the risk of death in CKD patients with diabetes and hypertension, which are the 2 leading causes of CKD. Recent studies suggest that correction of anemia improves patient quality of life and may delay the progression to end-stage renal disease. Anemia is often only treated in the late stages of CKD or after the initiation of renal replacement therapy. Thus, anemia of CKD is often unnoticed and lacks appropriate treatment. To practically manage high-risk patients with CKD and its associated cardiovascular diseases, it is mandatory to diagnose and appropriately treat anemia of CKD earlier. The optimal level of hemoglobin for greatest clinical benefit is unclear, but at present, it is recommended to remain > or = 11 g/dL. This paper provides recommendations for the diagnosis and management of anemia associated with CKD based on international practice guidelines.
贫血是慢性肾脏病(CKD)中常见的问题,且会随着肾功能下降而恶化。贫血增加了患有糖尿病和高血压的CKD患者的死亡风险,而糖尿病和高血压是CKD的两大主要病因。近期研究表明,纠正贫血可改善患者生活质量,并可能延缓进展至终末期肾病。贫血往往仅在CKD晚期或开始肾脏替代治疗后才得到治疗。因此,CKD相关性贫血常常未被察觉且缺乏适当治疗。为切实管理CKD高危患者及其相关心血管疾病,必须更早诊断并适当治疗CKD相关性贫血。目前尚不清楚能带来最大临床获益的血红蛋白最佳水平,但目前建议维持在≥11 g/dL。本文基于国际实践指南,对CKD相关性贫血的诊断和管理提供建议。